A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma — Stella

Home/Metastatic Urothelial Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Urothelial Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Sarcoma Oncology Center, Santa Monica, California

Key details

Phase

Safety & dosing

Sponsor

Vasgene Therapeutics, Inc

Enrollment target

~38 participants

Started

August 2020

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.